A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

NCT06215118 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elranatamab
DRUG: Iberdomide

Sponsor

Pfizer

Collaborators

[object Object]